WO2015151078A3 - Hydrophilic linkers for conjugation - Google Patents

Hydrophilic linkers for conjugation Download PDF

Info

Publication number
WO2015151078A3
WO2015151078A3 PCT/IB2015/054521 IB2015054521W WO2015151078A3 WO 2015151078 A3 WO2015151078 A3 WO 2015151078A3 IB 2015054521 W IB2015054521 W IB 2015054521W WO 2015151078 A3 WO2015151078 A3 WO 2015151078A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugation
hydrophilic linkers
linkers
hydrophilic
conjugates
Prior art date
Application number
PCT/IB2015/054521
Other languages
French (fr)
Other versions
WO2015151078A4 (en
WO2015151078A2 (en
Inventor
Robert Yongxin Zhao
Original Assignee
Suzhou M-Conj Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202011053870.7A priority Critical patent/CN112125929A/en
Priority to CN201580080839.3A priority patent/CN108026123B/en
Priority to EP15773860.0A priority patent/EP3307749A4/en
Priority to PCT/IB2015/054521 priority patent/WO2015151078A2/en
Priority to CA2989269A priority patent/CA2989269C/en
Priority to AU2015242210A priority patent/AU2015242210A1/en
Application filed by Suzhou M-Conj Biotech Co., Ltd filed Critical Suzhou M-Conj Biotech Co., Ltd
Priority to NZ737471A priority patent/NZ737471A/en
Publication of WO2015151078A2 publication Critical patent/WO2015151078A2/en
Publication of WO2015151078A3 publication Critical patent/WO2015151078A3/en
Publication of WO2015151078A4 publication Critical patent/WO2015151078A4/en
Priority to AU2021201765A priority patent/AU2021201765B2/en
Priority to AU2023200925A priority patent/AU2023200925A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided.
PCT/IB2015/054521 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation WO2015151078A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201580080839.3A CN108026123B (en) 2015-06-15 2015-06-15 Hydrophilic linkers for coupling
EP15773860.0A EP3307749A4 (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation
PCT/IB2015/054521 WO2015151078A2 (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation
CA2989269A CA2989269C (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
AU2015242210A AU2015242210A1 (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation
CN202011053870.7A CN112125929A (en) 2015-06-15 2015-06-15 Hydrophilic linkers for coupling
NZ737471A NZ737471A (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation
AU2021201765A AU2021201765B2 (en) 2015-06-15 2021-03-22 Hydrophilic Linkers for Conjugate
AU2023200925A AU2023200925A1 (en) 2015-06-15 2023-02-17 Hydrophilic Linkers for Conjugate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/054521 WO2015151078A2 (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation

Publications (3)

Publication Number Publication Date
WO2015151078A2 WO2015151078A2 (en) 2015-10-08
WO2015151078A3 true WO2015151078A3 (en) 2016-03-10
WO2015151078A4 WO2015151078A4 (en) 2016-07-14

Family

ID=54241395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/054521 WO2015151078A2 (en) 2015-06-15 2015-06-15 Hydrophilic linkers for conjugation

Country Status (6)

Country Link
EP (1) EP3307749A4 (en)
CN (2) CN112125929A (en)
AU (3) AU2015242210A1 (en)
CA (1) CA2989269C (en)
NZ (1) NZ737471A (en)
WO (1) WO2015151078A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7218919B2 (en) 2017-04-06 2023-02-09 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Conjugation of cytotoxic agents via bis-linkage

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
CA2878733C (en) 2012-07-12 2021-09-14 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
MX2018006218A (en) * 2015-12-04 2018-09-05 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds.
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
PE20190353A1 (en) 2016-04-15 2019-03-07 Macrogenics Inc NOVELTY B7-H3 JOINT MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
CN110167577B (en) * 2016-11-16 2024-05-10 普渡研究基金会 Ligand ionophore conjugates
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
AU2018287171B2 (en) * 2017-06-21 2024-03-28 Glykos Finland Oy Hydrophilic linkers and conjugates thereof
ES2877659T3 (en) 2017-12-01 2021-11-17 Abbvie Inc Glucocorticoid receptor agonist and its immunoconjugates
WO2019109415A1 (en) * 2017-12-04 2019-06-13 清华大学 Compound for targeted degradation of hmgcr and application thereof
EP3621652A4 (en) * 2017-12-31 2021-01-13 Hangzhou DAC Biotech Co, Ltd A conjugate of a tubulysin analog with branched linkers
CN110152014B (en) * 2018-02-13 2022-09-27 烟台市和元艾迪斯生物医药科技有限公司 anti-TRAILR 2 antibody-toxin-conjugate and its pharmaceutical use in anti-tumor therapy
WO2019157772A1 (en) * 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
CN108727376B (en) * 2018-05-21 2020-09-11 中国计量大学 9-azabicyclo [3.3.1] nonane coupled iodine-enriched compound and preparation method and application thereof
CN108676002B (en) * 2018-06-04 2020-09-15 中国计量大学 9-nitrogen (6' -amino) hexyl heterobicyclo [3.3.1] nonane coupled rhodamine B compound and application thereof
CN108864251B (en) * 2018-06-30 2022-06-14 大连理工大学 Aminopeptidase N activated prodrug compound and preparation method and application thereof
BR112021005655A2 (en) * 2018-09-27 2021-06-29 Pierre Fabre Medicament sulfomaleimide-based ligands and corresponding conjugates
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2022532342A (en) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compound
CN112386707B (en) * 2019-08-19 2023-08-11 辽宁医学诊疗科技研发中心有限公司 Tumor targeting polypeptide drug conjugate and preparation method thereof
CN110938035B (en) * 2019-10-28 2022-07-01 广西师范大学 9-benzenesulfonic acid-10-imidine hydrazone and synthetic method and application thereof
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113135990A (en) * 2020-01-20 2021-07-20 宁波鲲鹏生物科技有限公司 Liraglutide derivatives and preparation method thereof
CA3108168A1 (en) * 2020-02-05 2021-08-05 Yue Zhang Conjugates of cell-binding molecules with cytotoxic agents
CN113816990B (en) * 2021-03-22 2023-08-22 联宁（苏州）生物制药有限公司 Modified amino acids and their use in ADCs
MX2023011241A (en) 2021-03-23 2023-10-03 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds.
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114200126A (en) * 2021-12-09 2022-03-18 牟奕 Solid phase matrix for detecting N-type penicillin and cephalosporin antibiotic antibodies and preparation method thereof
WO2023129576A2 (en) * 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
CN115286669A (en) * 2022-07-15 2022-11-04 北京大学 Preparation method and application of antibody-macromolecule-drug conjugate
CN116773826B (en) * 2023-08-21 2023-11-17 迪亚莱博（张家港）生物科技有限公司 Latex turbidimetric biochemical kit for detecting anti-protease 3 antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034019A2 (en) * 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
WO2008070291A2 (en) * 2006-10-24 2008-06-12 Kereos, Inc. Improved linkers for anchoring targeting ligands
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003862A (en) * 1975-10-23 1977-01-18 Michigan Chemical Corporation N-substituted tetrahalophthalimides as flame retardants
CN104650113A (en) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 Maytansine derivative as well as preparation method and application thereof
NZ717003A (en) * 2013-09-02 2019-05-31 Hangzhou Dac Biotech Co Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
JP6733993B2 (en) 2014-10-03 2020-08-05 シンアフィックス ビー．ブイ． Sulfamide linker, conjugate of sulfamide linker, and method of preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034019A2 (en) * 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
WO2008070291A2 (en) * 2006-10-24 2008-06-12 Kereos, Inc. Improved linkers for anchoring targeting ligands
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHAO, ROBERT YONGXIN,.: "Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the tareted treatment of cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, 8 December 2011 (2011-12-08), pages 766 - 782, XP055041930, DOI: doi:10.1021/jm201284m *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7218919B2 (en) 2017-04-06 2023-02-09 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Conjugation of cytotoxic agents via bis-linkage

Also Published As

Publication number Publication date
WO2015151078A4 (en) 2016-07-14
EP3307749A4 (en) 2019-06-19
AU2021201765B2 (en) 2022-12-08
AU2015242210A1 (en) 2017-12-07
CA2989269C (en) 2020-09-22
AU2023200925A1 (en) 2023-03-23
CN108026123A (en) 2018-05-11
CN112125929A (en) 2020-12-25
CN108026123B (en) 2021-02-05
EP3307749A2 (en) 2018-04-18
CA2989269A1 (en) 2015-10-08
AU2021201765A1 (en) 2021-04-15
WO2015151078A2 (en) 2015-10-08
NZ737471A (en) 2022-02-25

Similar Documents

Publication Publication Date Title
WO2015151078A3 (en) Hydrophilic linkers for conjugation
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
EP3538080A4 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP3585424A4 (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SA518391159B1 (en) Affinity-Oligonucleotide Conjugates and Uses Thereof
EP3411074A4 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
MX2021010550A (en) Hydrophilic antibody-drug conjugates.
EP3801634A4 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
EP3595668A4 (en) Benzazepine compounds, conjugates, and uses thereof
WO2018109170A3 (en) Il-11ra antibodies
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
EP3867250A4 (en) Conjugation linkers containing 2,3-diaminosuccinyl group
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SG10201803042PA (en) Anti-tim-3 antibodies
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
EP3450460A4 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
EP3946460A4 (en) Improved conjugation linkers
EP3271329A4 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
EP3581208A4 (en) Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
EP3679053A4 (en) High affinity cxcr4 selective binding conjugate and method for using the same
WO2016164743A3 (en) Cd38 ligand-drug conjugates for targeted cancer therapy
EP3735987A4 (en) Amanitin antibody conjugate
IL272931A (en) Peptide conjugates, conjugation process, and uses thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2015242210

Country of ref document: AU

Date of ref document: 20150615

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2989269

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773860

Country of ref document: EP

Kind code of ref document: A2